Literature DB >> 8083125

Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast.

L J Solin1, A Fourquet, B McCormick, B Haffty, A Recht, D J Schultz, W Barrett, B L Fowble, R Kuske, M Taylor.   

Abstract

PURPOSE: The purpose of the present study is to evaluate the outcome of salvage treatment for local recurrence in the breast following the initial treatment of ductal carcinoma in situ (intraductal carcinoma) with breast-conserving surgery and definitive breast irradiation. METHODS AND MATERIALS: An analysis was performed of 42 local failures in the breast that occurred following the initial treatment of ductal carcinoma in situ (intraductal carcinoma) with breast-conserving surgery and definitive breast irradiation. At the time of the local recurrence, 23 cases (55%) showed invasive ductal carcinoma, and 19 cases (45%) showed intraductal carcinoma, one with associated Paget's disease. The surgical treatment at the time of local recurrence included mastectomy (n = 39), excision (n = 2), or other (n = 1). Adjuvant systemic therapy at the time of local recurrence included chemotherapy (n = 2), hormonal treatment (n = 7), both (n = 1), or none (n = 32). The median follow-up after salvage treatment was 3.7 years (mean = 4.0 years; range = 0.1-9.5 years).
RESULTS: The 5-year actuarial outcome following salvage treatment for the 42 local recurrences showed an overall survival rate of 78% and a cause-specific survival rate of 84%. The 5-year actuarial rate of freedom from distant metastases was 86%. None of the patients with histology of the local recurrence of intraductal carcinoma or with detection of the local recurrence with mammographic findings only developed distant metastatic disease after salvage treatment. The 5-year actuarial rate of freedom from chest wall recurrence following salvage mastectomy was 92%. All three of the patients who developed chest wall recurrence following salvage mastectomy also developed distant metastatic disease.
CONCLUSIONS: These results demonstrate that local recurrences following the initial treatment of ductal carcinoma in situ with breast-conserving surgery and definitive breast irradiation can be salvaged with high rates of survival, freedom from distant metastases, and freedom from chest wall recurrence. The results of salvage treatment support the use of breast-conserving surgery and definitive breast irradiation for the initial management of ductal carcinoma in situ of the breast.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083125     DOI: 10.1016/0360-3016(94)90512-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

Review 1.  Ductal carcinoma in situ of the breast.

Authors:  M J Silverstein
Journal:  BMJ       Date:  1998-09-12

Review 2.  Current management of ductal carcinoma in situ.

Authors:  A Barth; R J Brenner; A E Giuliano
Journal:  West J Med       Date:  1995-10

3.  Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast.

Authors:  N B Teo; B S Shoker; C Jarvis; J P Sloane; C Holcombe
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

4.  HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.

Authors:  E Rakovitch; S Nofech-Mozes; W Hanna; S Narod; D Thiruchelvam; R Saskin; J Spayne; C Taylor; L Paszat
Journal:  Br J Cancer       Date:  2012-02-23       Impact factor: 7.640

5.  Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery.

Authors:  Jung Yeon Kim; Kyeongmee Park; Guhyun Kang; Hyun-Jung Kim; Geumhee Gwak; Young-Joo Shin
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.